A Prospective Study to Establish a New-Onset Diabetes Cohort: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer
Open accessAbstract
The National Cancer Institute and the National Institute for Diabetes and Digestive and Kidney Diseases initiated the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) in 2015 (the CPDPC's origin, structure, governance, and research objectives are described in another article in this journal). One of the key objectives of CPDPC is to assemble a cohort of 10,000 subjects 50 years or older with new-onset diabetes, called the NOD cohort. Using a define, enrich, and find early detection approach, the aims of the NOD study are to ( a ) estimate the 3-year probability of pancreatic ductal adenocarcinoma (PDAC) in NOD ( define ), (b) establish a biobank of clinically annotated biospecimens from presymptomatic PDAC and control new-onset type 2 diabetes mellitus subjects, (c) conduct phase 3 validation studies of promising biomarkers for identification of incident PDAC in NOD patients ( enrich ), and (d) provide a platform for development of a future interventional screening protocol for early detection of PDAC in patients with NOD that incorporates imaging studies and/or clinical algorithms ( find ). It is expected that 85 to 100 incidences of PDAC will be diagnosed during the study period in this cohort of 10,000 patients.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The currently used blood-based biomarker, CA 19-9, accurately predicts only 65% of those with early disease when surgical treatment is a viable option.
“and the currently used blood-based biomarker, CA 19-9, accurately predicts only 65% of those with early disease when surgical treatment is a viable option.3,167”
From Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review (2021) · cites this paper as [167]
The Biomarkers for Early Detection of PDAC section identifies CA 19-9 as a leading biomarker and says its sensitivity for asymptomatic PDAC is low. It does not report 65% sensitivity in surgically treatable early disease; instead, it assumes 50% sensitivity for study planning in the new-onset diabetes population. The Background and Significance section separately explains why detection while cancer is resectable matters. (LLM, conf=0.88)
Experimental — accuracy not yet measuredSurgery is the only therapy to date associated with a durable long-term outcome.
“This result is based on the findings that surgery is the only therapy to date associated with a durable long-term outcome.”
From Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review (2021) · cites this paper as [167]
The Background and Significance section says that detecting pancreatic cancer while it is still resectable permits therapeutic options that result in long-term survival. It does not say surgery is the only such therapy or establish that the outcome is durable. (LLM, conf=0.84)
Experimental — accuracy not yet measuredSeveral studies have shown that early detection of PDAC improves outcome.
“Several studies have shown that early detection of PDAC improves outcome.”
From Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review (2021) · cites this paper as [167]
The Background and Significance section says detecting PDAC while it is resectable could permit treatment leading to long-term survival. The Biomarkers for Early Detection of PDAC section describes improved survival as an anticipated benefit, not an outcome that several studies have shown. (LLM, conf=0.87)
Experimental — accuracy not yet measuredThe US Consortium on Chronic Pancreatitis, Diabetes, and Pancreatic Cancer has initiated a longitudinal cohort study, the New-Onset Hyperglycemia and Diabetes Cohort, to discover and validate high-sensitive and specificity biomarkers to identify patients with a high probability of having early PDAC.
“In a major effort to developing tests (liquid biopsy and imaging), the US Consortium on Chronic Pancreatitis, Diabetes, and Pancreatic Cancer has initiated a longitudinal cohort study, the New-Onset Hyperglycemia and Diabetes Cohort, to discover and validate high-sensitive and specificity biomarkers to identify patients with a high probability of having early PDAC.167”
From Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review (2021) · cites this paper as [167]
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredThe size of the lesion at the time of surgery is a predictor of long-term survival.
“Furthermore, the size of the lesion at the time of surgery is a predictor of long-term survival.3,166,167”
From Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review (2021) · cites this paper as [167]
The Background and Significance section says that detecting pancreatic cancer while it is resectable can permit treatments leading to long-term survival. It does not address whether lesion size at surgery predicts survival; searches for lesion size, surgical resection, and prognosis found no such passage. Page numbers were unavailable in our copy. (LLM, conf=0.76)
Experimental — accuracy not yet measured
Studies underway in the USA and UK are actively investigating how best to detect pancreatic ductal adenocarcinoma in individuals with new-onset diabetes.
“However, studies underway in the USA61 and UK62 are actively investigating how best to detect pancreatic ductal adenocarcinoma in individuals with new-onset diabetes.”
From Early detection of pancreatic cancer (2020) · cites this paper as [61]
The predicted incidence of pancreatic ductal adenocarcinoma among people with new-onset diabetes after age 50 is only 1-2% over 3 years.
“although the incidence of pancreatic ductal adenocarcinoma in this group is predicted to be only 1–2% over a 3-year period.”
From Early detection of pancreatic cancer (2020) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Phases of Biomarker Development for Early Detection of Cancer
Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., & Yasui, Y. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1054 · Cited by 1,686 · see citing works
Self-citationThe National Lung Screening Trial: Overview and Study Design
National Lung Screening Trial Research Team (2010) · Radiology · doi:10.1148/radiol.10091808 · Cited by 1,280 · see citing works
A Comparison of Fecal Occult-Blood Tests for Colorectal-Cancer Screening
Allison, J. E., Tekawa, I. S., Ransom, L. J., & Adrain, A. L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601183340304 · Cited by 620 · see citing works
Probability of Pancreatic Cancer Following Diabetes: A Population-Based Study
Chari, S. T., Leibson, C. L., Rabe, K. G., Ransom, J., de Andrade, M., & Petersen, G. M. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.05.007 · Cited by 603 · see citing works
Self-citationNew-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer
Pannala, R., Basu, A., Petersen, G. M., & Chari, S. T. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70337-1 · Cited by 562 · see citing works
Self-citationDiabetes and the Risk of Pancreatic Cancer
Gullo, L., Pezzilli, R., & Morselli‐Labate, A. M. (1994) · New England Journal of Medicine · doi:10.1056/nejm199407143310203 · Cited by 366 · see citing works
New insights into pancreatic cancer-induced paraneoplastic diabetes
Sah, R. P., Nagpal, S. J. S., Mukhopadhyay, D., & Chari, S. T. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.49 · Cited by 336 · see citing works
Self-citationEarly Detection of Sporadic Pancreatic Cancer: Summative Review
Chari, S. T., Kelly, K., Hollingsworth, M. A., Thayer, S. P., Ahlquist, D. A., Andersen, D. K., Batra, S. K., Brentnall, T. A., Canto, M., Cleeter, D. F., et al. (2015) · Pancreas · doi:10.1097/mpa.0000000000000368 · Cited by 295 · see citing works
Self-citationSharma, A., Smyrk, T. C., Levy, M. J., Topazian, M. A., & Chari, S. T. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.025 · Cited by 204 · see citing works
Ogawa, Y., Tanaka, M., Inoue, K., Yamaguchi, K., Chijiiwa, K., Mizumoto, K., Tsutsu, N., & Nakamura, Y. (2002) · Cancer · doi:10.1002/cncr.10493 · Cited by 108 · see citing works
Nolen, B. M., Brand, R. E., Prosser, D., Velikokhatnaya, L., Allen, P. J., Zeh, H. J., Grizzle, W. E., Lomakin, A., & Lokshin, A. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094928 · Cited by 94 · see citing works
Self-citationNew-onset diabetes in pancreatic cancer: A study in the primary care setting
Aggarwal, G., Rabe, K. G., Petersen, G. M., & Chari, S. T. (2012) · Pancreatology · doi:10.1016/j.pan.2012.02.003 · Cited by 90 · see citing works
Self-citationIslet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer
Chari, S. T., Klee, G. G., Miller, L. J., Raimondo, M., & DiMagno, E. P. (2001) · Gastroenterology · doi:10.1053/gast.2001.27210 · Cited by 87 · see citing works
Self-citationDamiano, J., Bordier, L., Berre, J. P. L., Margery, J., Dupuy, O., Mayaudon, H., & Bauduceau, B. (2004) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70111-8 · Cited by 58 · see citing works
Illés, D., Terzin, V., Holzinger, G., Kosár, K., Róka, R., Zsóri, G., Ábrahám, G., & Czakó, L. (2015) · Pancreatology · doi:10.1016/j.pan.2015.12.005 · Cited by 54 · see citing works
A web-based system for managing and co-ordinating multiple multisite studies
Winget, M., Kincaid, H., Lin, P., et al. (2005) · Clinical Trials · doi:10.1191/1740774505cn62oa · Cited by 28 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Early Detection of Pancreatic Cancer: Opportunities and Challenges
Singhi, A. D., Koay, E. J., Chari, S. T., & Maitra, A. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.259 · Cited by 841 · see citing works
Self-citationEarly detection of pancreatic cancer
Pereira, S. P., Oldfield, L., Ney, A., Hart, P. A., Keane, M. G., Pandol, S. J., Li, D., Greenhalf, W., Jeon, C. Y., Koay, E. J., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30416-9 · Cited by 482 · see citing works
Self-citationArtificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review
Kenner, B., Chari, S. T., Kelsen, D., Klimstra, D. S., Pandol, S. J., Rosenthal, M., Rustgi, A. K., Taylor, J. A., Yala, A., Abul-Husn, N., et al. (2021) · Pancreas · doi:10.1097/mpa.0000000000001762 · Cited by 158 · see citing works
Self-citationDiabetes, weight change, and pancreatic cancer risk
Yuan, C., Babic, A., Khalaf, N., Nowak, J. A., Brais, L. K., Rubinson, D. A., Ng, K., Aguirre, A. J., Pandharipande, P. V., Fuchs, C. S., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2948 · Cited by 150 · see citing works
Singh, D. P., Sheedy, S., Goenka, A. H., Wells, M., Lee, N. J., Barlow, J., Sharma, A., Kandlakunta, H., Chandra, S., Garg, S. K., et al. (2020) · Pancreatology · doi:10.1016/j.pan.2020.07.410 · Cited by 62 · see citing works
Self-citationChari, S. T., Maitra, A., Matrisian, L. M., Shrader, E. E., Wu, B. U., Kambadakone, A., Zhao, Y.-Q., Kenner, B., Rinaudo, J. A. S., Srivastava, S., et al. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106659 · Cited by 62 · see citing works
Self-citationSchwartz, N. R. M., Matrisian, L. M., Shrader, E. E., Feng, Z., Chari, S., & Roth, J. A. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7798 · Cited by 43 · see citing works
Self-citationIs screening for pancreatic cancer in high-risk individuals one step closer or a fool's errand?
Hart, P. A., & Chari, S. T. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.09.024 · Cited by 32 · see citing works
Self-citation
- Authors
- Maitra, A., Sharma, A., Brand, R. E., Van Den Eeden, S. K., Fisher, W. E., Hart, P. A., Hughes, S. J., Mather, K. J., Pandol, S. J., Park, W. G., Feng, Z., Serrano, J., Rinaudo, J. A. S., Srivastava, S., & Chari, S. T.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Mayo Clinic (US)
- University of Pittsburgh Medical Center (US)
- Division of Research, Kaiser Permanente Northern California, Oakland, CA;
- Baylor College of Medicine (US)
- The Ohio State University Wexner Medical Center (US)
- University of Florida Health (US)
- Indiana University Indianapolis (US)
- Cedars-Sinai Medical Center (US)
- Stanford Medicine (US)
- Fred Hutch Cancer Center (US)
- Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; and
- National Cancer Institute (US)
- Corresponding author
- Maitra, Anirban
- Mather, Kieren J.
- ORCID
- Venue
- Pancreas
- Published
- 2018-11
- Volume
- 47
- Issue
- 10
- Pages
- 1244-1248
- ISSN
- 0885-3177 (ISSN-L)
- 1536-4828
- PMC
- PMC6432934
- OpenAlex
- W2896405398
- Cited by
- 93
- References
- 16
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 6 · 2023: 8 · 2022: 12 · 2021: 23 · 2020: 13 · 2019: 6 · 2018: 3
- FWCI
- 4.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Pancreas (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion)
- Funders
- National Cancer Institute (P01CA163200)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK108327, U01DK108326, U01DK108320, U01DK108332, L30 DK118657, U01DK108300, U01DK108306, U01DK108323, U01DK108314, U01DK108328, U01DK108288, P01DK098108)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Keywords
- pancreatic ductal adenocarcinoma, early cancer detection, pancreatic cancer screening, chronic pancreatitis, biomarkers, biobanks, pancreatic cancer incidence
- MeSH terms
- Blood Specimen Collection, Diabetes Mellitus, Type 2, Humans, Middle Aged, Pancreatic Neoplasms, Prospective Studies, Research Design, Carcinoma, Pancreatic Ductal, Biomedical Research, Early Diagnosis, Pancreatitis, Chronic, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
